1. Home
  2. STRA vs SNDX Comparison

STRA vs SNDX Comparison

Compare STRA & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STRA

Strategic Education Inc.

HOLD

Current Price

$80.32

Market Cap

1.8B

Sector

Real Estate

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$23.66

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRA
SNDX
Founded
2017
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
STRA
SNDX
Price
$80.32
$23.66
Analyst Decision
Buy
Strong Buy
Analyst Count
2
12
Target Price
$96.50
$84.17
AVG Volume (30 Days)
302.2K
1.2M
Earning Date
04-23-2026
05-04-2026
Dividend Yield
2.98%
N/A
EPS Growth
15.85
11.56
EPS
5.41
N/A
Revenue
$997,137,000.00
$172,352,000.00
Revenue This Year
$4.71
$112.05
Revenue Next Year
$2.48
$51.24
P/E Ratio
$14.85
N/A
Revenue Growth
57.23
627.84
52 Week Low
$72.17
$8.59
52 Week High
$92.98
$25.16

Technical Indicators

Market Signals
Indicator
STRA
SNDX
Relative Strength Index (RSI) 50.00 62.04
Support Level $79.98 $19.46
Resistance Level $84.71 $25.16
Average True Range (ATR) 3.18 1.24
MACD -0.01 0.15
Stochastic Oscillator 35.02 74.79

Price Performance

Historical Comparison
STRA
SNDX

About STRA Strategic Education Inc.

Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: